Skip to main content
Equibles
NEUP logo

NEUP · Neuphoria Therapeutics Inc.

Track NEUP — free

Use NEUP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NEUP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.73 +0.00 (+0.00%) At close · Sep 11
Rebalance outlook locked
Market Cap
$20.16M
Shares
5.40M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.73 Open$3.78 Day$3.72–3.78 52W close$3.30–20.00 Avg vol 30d43K Short int65K · 1.2% float · 1.0d Short vol4% DataDec 2024–Sep 2026 Filing10-Q · May 15

Raw chart and full-history price indicators begin at the captured split on Dec 24, 2024; bars on opposite sides are not compared.

Up next

Latest filing: 10-Q
filed May 15, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+214.8%
Year over year · more shares
Price change (1Y)
-73.2%
Trailing year
Short interest
1.2%
Latest settlement · 1.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −13%
below
Price vs 50-day avg −0%
below
RSI (14) 42
neutral
MACD trend Negative
52-week position 3%
near low
Momentum
relative strength
Very Weak
1-month return −3%
trailing
6-month return −19%
trailing
YTD return −4%
this year
Relative strength −37%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+16% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.20% of float · ▲ +53.8% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
22 holders — near 1-yr high, broad support
Squeeze score 49
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 119%
annualized · 1-yr
Max drawdown −84%
past year
ATR 3.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−13% Bearish
Price vs 50-day avg
−0% Neutral
RSI (14)
42 Neutral
MACD trend
Negative Bearish
52-week position
3% Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+16% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.20% of float · ▲ +53.8% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
22 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $4 · 3% Range high $20
vs 200-day avg -13% vs 50-day avg 0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NEUP
Neuphoria Therapeutics Inc.
this stock
$20.16M -3.9% — — 1.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
22
% held
36.9%
Net QoQ
+236.1K sh
Top holder
Lynx1 Capital Management…
Held Float
View
Held by Funds
Fund positions
7
View
Short & Settlement
Short Interest Rising
Shares short
64.6K
Days to cover
1.0d
Change
+22.6K sh
View
Short Volume
Short vol %
4%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
129
Value
$491
As of
Aug 13, 2026
View
Off-Exchange
Off-exchange %
32.5%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$15.6M
Net income (FY)
$-400.0K
EPS diluted
$-0.23
View
Filings
SEC Filings
Latest
8-K
Filed
Jul 24, 2026
This year
5
View

Performance

Raw-price comparisons begin at the captured split on Dec 24, 2024; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
NEUP -0.8% -2.6% -19.1% -0.8% -3.9%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY +0.4% -0.9% -36.9% -0.4% -16.0%
Key facts CIK 1191070 CUSIP 64136E102 13F (30d) 16 filings 16 filers Visit website Investor relations